Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

Francis J. Giles; Julie M. Vose; Kim Anh Do; Marcella M. Johnson; Taghi Manshouri; Gregory Bociek; Philip J. Bierman; Susan M. O'Brien; Hagop M. Kantarjian; James O. Armitage; Maher Albitar

doi:10.1016/j.leukres.2003.11.002

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

Francis J. Giles, Julie M. Vose, Kim Anh Do, Marcella M. Johnson, Taghi Manshouri, Gregory Bociek, Philip J. Bierman, Susan M. O'Brien, Hagop M. Kantarjian, James O. Armitage, Maher Albitar

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.

Original language	English (US)
Pages (from-to)	595-604
Number of pages	10
Journal	Leukemia Research
Volume	28
Issue number	6
DOIs	https://doi.org/10.1016/j.leukres.2003.11.002
State	Published - Jun 2004

Keywords

Angiogenin
HGF
Hodgkin's
Lymphoma
Prognosis
Survival
VEGF
bFGF

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2003.11.002

Cite this

@article{3d2ee74e5dce4b91bfdbe87618f73fae,

title = "Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma",

abstract = "Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.",

keywords = "Angiogenin, HGF, Hodgkin's, Lymphoma, Prognosis, Survival, VEGF, bFGF",

author = "Giles, {Francis J.} and Vose, {Julie M.} and Do, {Kim Anh} and Johnson, {Marcella M.} and Taghi Manshouri and Gregory Bociek and Bierman, {Philip J.} and O'Brien, {Susan M.} and Kantarjian, {Hagop M.} and Armitage, {James O.} and Maher Albitar",

year = "2004",

month = jun,

doi = "10.1016/j.leukres.2003.11.002",

language = "English (US)",

volume = "28",

pages = "595--604",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

AU - Giles, Francis J.

AU - Vose, Julie M.

AU - Do, Kim Anh

AU - Johnson, Marcella M.

AU - Manshouri, Taghi

AU - Bociek, Gregory

AU - Bierman, Philip J.

AU - O'Brien, Susan M.

AU - Kantarjian, Hagop M.

AU - Armitage, James O.

AU - Albitar, Maher

PY - 2004/6

Y1 - 2004/6

N2 - Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.

AB - Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.

KW - Angiogenin

KW - HGF

KW - Hodgkin's

KW - Lymphoma

KW - Prognosis

KW - Survival

KW - VEGF

KW - bFGF

UR - http://www.scopus.com/inward/record.url?scp=11144354408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354408&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.11.002

DO - 10.1016/j.leukres.2003.11.002

M3 - Article

C2 - 15120936

AN - SCOPUS:11144354408

SN - 0145-2126

VL - 28

SP - 595

EP - 604

JO - Leukemia Research

JF - Leukemia Research

IS - 6

ER -

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this